share_log

CytomX Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Announced Initial Data From the Ongoing CX-904 Phase 1a Dose Escalation Clinical Study, Demonstrating a Favorable Safety Profile and...

Benzinga ·  May 8 17:03

CytomX Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Announced Initial Data From the Ongoing CX-904 Phase 1a Dose Escalation Clinical Study, Demonstrating a Favorable Safety Profile and Confirmed Anti-cancer Activity.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment